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Abstract
In Sierra Leone, the Ebola virus disease (EVD) outbreak occurred with substantial differences
between districts with someone even not affected. To monitor the epidemic, a community
event-based surveillance system was set up, collecting data into the Viral Haemorrhagic
Fever (VHF) database. We analysed the VHF database of Tonkolili district to describe the epi-
demiology of the EVD outbreak during July 2014–June 2015 (data availability). Multivariable
analysis was used to identify risk factors for EVD, fatal EVD and barriers to healthcare access,
by comparing EVD-positive vs. EVD-negative cases. Key-performance indicators for EVD
response were also measured. Overall, 454 EVD-positive cases were reported. At multivariable
analysis, the odds of EVD was higher among those reporting contacts with an EVD-positive/
suspected case (odds ratio (OR) 2.47; 95% confidence interval (CI) 2.44–2.50; P < 0.01) and
those attending funeral (OR 1.02; 95% CI 1.01–1.04; P < 0.01). EVD cases from Kunike chief-
dom had a lower odds of death (OR 0.22; 95% CI 0.08–0.44; P < 0.01) and were also more
likely to be hospitalised (OR 2.34; 95% CI 1.23–4.57; P < 0.05). Only 25.1% of alerts were gen-
erated within 1 day from symptom onset. EVD preparedness and response plans for Tonkolili
should include social-mobilisation activities targeting Ebola/knowledge-attitudes-practice dur-
ing funeral attendance, to avoid contact with suspected cases and to increase awareness on
EVD symptoms, in order to reduce delays between symptom onset to alert generation and
consequently improve the outbreak-response promptness.
Introduction
Ebola virus disease (EVD) is a life-threatening illness due to Ebola virus (EBOV) [1]. Human
EBOV infection is accidental, through direct contact with infected animals involved in the
epi-enzootic viral cycle [2]. Once entered into the humans’ transmission chain, EBOV spreads
through direct or indirect contact with bodily fluids of symptomatic or deceased EVD persons
[3]. The EVD incubation period is 2–21 days, and humans are infectious only when symptom-
atic, but the long-lasting persistence of EBOV-RNA in semen of male EVD survivors raised
concerns on sexual transmission after EVD recovery [4].
The 2013–2016, West-African EVD epidemic was the largest, deadliest and most complex
outbreak since EBOV was discovered in 1976 [5]. Differently from other outbreaks, the
West-Africa’s 2013–2016 EVD outbreak involved urban impoverished and overcrowded
areas of multiple countries, as well as isolated villages (thanks to recent improvement of con-
nections in these countries), causing more cases and deaths than all the 23 previous EVD out-
breaks combined. It began in Guinea in late 2013, spreading to Liberia and Sierra Leone during
early 2014 [6], with smaller linked outbreaks in Nigeria, Mali and Senegal; imported cases were
also reported in Europe and USA, with secondary infections of health care workers (HCWs),
but without further spread [7]. On 8 August 2014, the World Health Organization (WHO)
declared the West-African EVD outbreak a Public Health Emergency of International
Concern (PHEIC) [8].
First EVD cases in Sierra Leone were reported from Kailahun district in May 2014 [9] and
the highest incidence at national level was reached during August–December 2014, after which
it declined as a result of the rapid scale-up of isolation, treatment and safe burial capacity in
the country [10]. When the PHEIC status was declared over (29 March 2016) [11], the three
West-African countries globally accounted for 28 610 EVD cases and 11 308 related deaths,
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with Sierra Leone reporting the highest burden of disease (14 124
cases and 3955 related deaths) [3]. The outbreak had devastating
impact on the health systems and pronounced socio-economic
effects in the three West-African countries [12].
Located in the centre of Sierra Leone, Tonkolili district borders
with seven districts, is divided in 11 chiefdoms with a population
of 455 383 people (Fig. S1) [13].
Although Tonkolili accounted for 5.2% of EVD cases and 4.5%
of related deaths reported in the country [14], during the epidemic it
experienced for three times the identification of new EVD cases
(one linked to a transmission chain of Freetown and two with
unknown origin) after having been declared as EVD-free district,
with the last case reported on 14 January 2016, after that the
WHO declared the end of Ebola transmission in the country
(7 November 2015) [15, 16]. These recrudescences were of inter-
national concern and determined a change in the response prac-
tices in terms of number of contacts traced and number of staff
rapidly deployed for the response [17].
To monitor the EVD epidemic, the Ministries of Health
(MoH) of Sierra Leone, Guinea and Liberia, the Centers for
Disease Control and Prevention (CDC) and the WHO, set up a
community event-based surveillance (CEBS) system using the
Epi Info Viral Haemorrhagic Fever (VHF) application (http://
epiinfovhf.codeplex.com/) [18]. The system collects demographic,
epidemiological, clinical and laboratory information on suspected
EVD cases, and data allowing measuring the MoH and WHO
key-performance indicators for EVD response [19]. The system
is implemented at district level through the district Ebola response
centre (DERC), with the support of WHO/CDC epidemiologists
and the district health management team (DHMT) [20].
This study presents EVD surveillance data from the VHF
database of Tonkolili district, Sierra Leone, with the principal
objectives to describe the epidemiology of the EVD outbreak
into the district during July 2014–June 2015 (data availability),
to identify risk factors for EVD, fatal EVD and to assess barriers
to healthcare access among EVD cases. Secondary objectives were
to measure the MoH/WHO key-performance indicators for EVD
response, and to present strategic analyses that can be performed
from the VHF database, in order to guide decision making for
national and international partners planning and implementing
the response, also in terms of future preparedness.
Methods
Data collection: the EVD CEBS and the Epi Info VHF
application
The EVD CEBS works by detecting alerts generated in the com-
munity and/or in healthcare facilities (HCF)/Ebola Treatment
Centre/Unit (ETC/ETU) [21]. According to the WHO [22], an
EVD alert is defined as: any person with illness onset of fever
and no response to treatment of usual causes of fever in the area.
OR at least one of the following signs: bleeding, bloody diar-
rhoea, bleeding into urine
OR any sudden death.
Alerts are collected at the DERC through the Ebola-hotline
(117) and screened by trained surveillance officers. Only if the
alert meets the EVD definition of suspected/probable case, trained
case investigators and/or contact tracers perform the case investi-
gation using a standardised form. In parallel, a clinical sample is
collected (blood for alive and oral swab for dead patients) and
sent to the district’s reference laboratory for confirmation through
real-time reverse-transcriptase polymerase chain reaction
(RT-PCR) test specific for EBOV [23].
Investigated alerts are daily reported to the WHO/CDC
Epidemiologist (surveillance pillar) that also receives and matches
the laboratory results in order to assign the final case classifica-
tion. There are four final case classifications according to the
WHO EVD case definition [22]:
SUSPECTED CASE: any person, alive or dead, suffering or
having suffered from a sudden onset of high fever and having
had contact with:
–a suspected, probable or confirmed Ebola case;
–a dead or sick animal (for Ebola)
OR: any person with sudden onset of high fever and at least
three of the following symptoms:
headaches, vomiting, anorexia/loss of appetite, diarrhoea, leth-
argy, stomach pain, aching muscles or joints, difficulty swallow-
ing, breathing difficulties, hiccup
OR: any person with inexplicable bleeding
OR: any sudden, inexplicable death.
PROBABLE CASE: any suspected case evaluated by a clinician
OR: any deceased suspected case (where it has not been pos-
sible to collect specimens for laboratory confirmation) having
an epidemiological link with a confirmed case.
LABORATORY-CONFIRMED CASE (EVD+): any suspected
or probably cases with a positive laboratory result. Laboratory-
confirmed cases must test positive for the virus antigen, either
by detection of virus RNA by RT-PCR, or by detection of IgM
antibodies directed against Marburg or Ebola.
NON-CASE (EVD–): any suspected or probable case with a
negative laboratory result. ‘Non-case’ showed no specific anti-
bodies, RNA or specific detectable antigens.
Epidemiological, clinical and laboratory data are finally
entered into the VHF database by a trained data-clerk and double
checked with the WHO/CDC epidemiologist.
Alert’s-related variables entered into the VHF database include
demographic (e.g. gender, age, residence, occupation), epidemio-
logical and clinical information, as the date of symptom onset, the
clinical presentations, the outcome (and eventually date, place of
death and of the burial), laboratory results and laboratory turn-
around time, the number of contacts traced and whether the
patient was hospitalised (and eventually date of hospitalisation)
and was in a contacts tracing list. Finally, the following informa-
tion on risk factors is collected: (1) direct contact with known or
suspected/probable EVD case, including the date of exposure, (2)
funeral attendance touching/carrying the body.
Data analysis
We retrospectively analysed alerts reported into the VHF database
of Tonkolili district during the period 1 July 2014–30 June 2015
(epi-week 27, 2014 to epi-week 26, 2015). Incidence, mortality
and hospitalisation rates per 100 000 inhabitants were calculated
using the 2015 population data (only available by chiefdom) pro-
vided by the DHMT of Tonkolili.
Risk factors for EVD+, fatal EVD+ and barriers to healthcare
access among EVD+ cases were assessed through univariate (χ2)
and multivariable analysis. Variables with a P-value <0.2 at the
univariate analysis were included in a multivariable stepwise
regression model, with a P-value >0.10 for backward elimination
[24]. As dependent variables we used: EVD+ vs. EVD− cases to
assess risk factors for EVD+; EVD+ dead vs. EVD+ alive cases
to assess death’s risk factors among EVD+ cases; hospitalised
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EVD+ vs. non-hospitalised EVD+ cases to evaluate barriers to
healthcare access among EVD+ cases. For the hospitalisation
and death analyses, we also assessed the symptoms (one vs. all
the others) associated with these two outcomes, adjusting by
age groups and gender.
Independent variables were: gender, age group (<6, 6–15, 16–
30, >30years), chiefdom of residence (Gbonkolenken, Kafe
Simiria, Kalansogoia, Kholifa Mabang, Kholifa Rowalla, Kunike,
Kunike Barina, Malal Mara, Sambaya Bendugu, Tane, Yoni and
‘outside district’), occupation (HCW/other occupation), hospital-
isation (yes/no), time interval from symptom onset to hospitalisa-
tion (⩾10; 3–9; ⩽2 days), clinical presentations (symptoms), and
whether in the 21 days before symptom onset the patient attended
a funeral touching the body and/or had contact with a confirmed/
suspected/probable EVD case.
For EVD+ cases with a known exposition timing, we also cal-
culated the incubation period.
Finally, the following MoH and WHO key-performance indi-
cators for EVD response were measured:
1. Percentage of alert generated within 1 day from symptoms
onset
2. Number and percentage of HCWs infected
3. Percentage of samples tested within 1 day of collection
4. Percentage of deaths buried within 1 day
5. Percentage of lives alert tested for EBOV
6. Percentage of deaths alert tested for EBOV
7. Percentage of reported community deaths that were tested for
EBOV
8. Percentage of new confirmed cases from registered contacts
9. Number of hospitalised within 3 days from symptom onset
10. Reporting the case fatality rate among hospitalised EVD+
cases
11. Reporting the number of Ebola survivors by gender, age
group, chiefdom
12. Reporting the number of contacts traced per EVD+ case
To evaluate failures of the surveillance system over the time
and by place, the achievement of indicators was assessed by trime-
sters and chiefdom using a logistic regression model, adjusting by
age group and gender. Indicators included in this analysis were
numbers: 1, 3, 5, 6, 7, 9.
The others were excluded because close to 100% or not suit-
able for logistic regression analysis. Results were expressed in
terms of odds ratios (ORs), with 95% confidence interval (95%
CI). Statistical significance was set at P-value <0.05. R-software
(version 3.3.1) was used for data analysis.
Ethical approval
Ethical clearance was obtained from: Sierra Leone Ethics and
Scientific Review Committee; MoH; Directorate of Policy,
Planning and Information (DPPI). Informed consent was not
requested because data were collected in the framework of a
national surveillance system.
Results
During the 1-year study period, 4550 alerts were reported and
classified as follows: 454 (10%) EVD+, 3344 (73.5%) EVD–, 53
(1.2%) probable and 699 (15.4%) suspected cases (Table 1).
Overall, 40.2% of alerts were from two chiefdoms (Kholifa
Rowalla 20.3%; Yoni 19.9%), concerned people aged >30 years
(40.5%) and dead persons (63.7%). HCWs represented the 1.2%
(n = 53) of the study population; of them, 11 (20.8%) were EVD+.
The distribution of EVD+ cases was proportioned between male
(51.4%) and female (48.6%), whilst 35.5% of EVD+ alert was
reported among those aged <6 years.
Figure 1 shows the number of alert by epi-week and case
definition.
Alerts increased gradually with time: from six (0.1%) in July
2014, to 332 (7.3%) in October 2014, 531 (11.7%) in March
2015, reaching the peak in June 2015 (n = 609; 13.4%). The first
EVD+ alert was a 14-year-old female from Kholifa Rowalla chief-
dom (reported on 19 August 2014). In September 2014, 56 EVD+
additional cases were reported, with a district incidence rate (IR)
of 147.6/100 000 inhabitants; then the EVD+ case count
increased, with the higher IR during October (n = 152; IR =
400.5/100 000) and November 2014 (n = 149; IR = 392.6/100
000). After that, the EVD+ case count decreased continuously:
63 EVD+ cases (IR = 168.6/100 000) in December 2014, 24
(IR = 63.2/100 000) in January 2015 and six (IR = 15.8/100 000)
in February 2015. The last recorded EVD+ case was imported
from Western Area Rural district in Yoni chiefdom on 15
March 2015 (epi-week 12).
The average EVD+ R during the study period (Table 2) was
99.7/100 000 inhabitants (range: 0.0 in Kalansogoia and
Sambaya Bendugu chiefdoms, to 209.0 in Kholifa Rowalla),
while the average EVD+ mortality rate was 20.4/100 000 inhabi-
tants (range: 0.0 in the chiefdoms of Kalansogoia, Kholifa
Mabang and Sambaya Bendugu, to 48.1 in Kholifa Rowalla) and
the average EVD+ hospitalisation rate 66.5/100 000 inhabitants
(range: 8.1 in Kafe Simiria to 127.6 in Tane) with two-thirds of
EVD+ cases hospitalised (n = 303/454; 66.7%).
In two chiefdoms (Kalansogoia, Sambaia Bendugu), no EVD+
cases were reported. Globally, 9 (2.0%) EVD+ cases were
imported from other Sierra-Leonean districts (five Bombali, one
Kono, two Western Area Urban and one Western Area Rural).
Out of the 454 EVD+ cases, 93 died, determining an EVD+
case fatality ratio (CFR) of 24.5% (range: 0.0% in Kholifa
Mabang (n = 0/3) to 40% in Kafe Simiria (n = 2/5)).
The analysis of key time periods among EVD+ cases showed a
median interval from symptom onset to death of 6.0 days (range:
0–20); a median interval form symptom onset to hospitalisation
of 3.0 days (range: 0–21) and a median incubation period of
11 days (range: 4–17).
Risk factors and symptoms associated with EVD+
Table 3 shows the risk factors associated with EVD+.
At the multivariable analysis, no difference was found by gen-
der and chiefdom of residence; whereas, those aged 16–30 years
had a higher odd of being EVD+ (OR 1.02; 95% CI 1.00–1.03;
P < 0.05). In comparison to other occupations, HCWs were 10%
less likely to become EVD+ (OR 0.90; 95% CI 0.86–0.94;
P < 0.01). Having had a contact with an EVD+ or suspected/prob-
able case increased the odds of being EVD+ (OR 2.47; 95% CI
2.44–2.50; P < 0.01), as well as attending a funeral and touch-
ing/carrying the body (OR 1.02; 95% CI 1.01–1.04; P < 0.01).
Risk factors and symptoms associated with death among
EVD+cases
Table 4 shows the risk factors (section A) and symptoms (section
B) associated with death among EVD+ cases.
Epidemiology and Infection 3
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At the multivariable analysis, only two risk factors remained
statistically significant: EVD+ cases from Kunike chiefdom had
a lower odds of death (OR 0.22; 95% CI 0.08–0.44; P < 0.01);
whilst the odd of death was inversely proportional to the duration
of the time interval from symptom onset to hospitalisation: the
longer was this interval, the lower was the risk of death (⩾10
days; OR 0.08; 95% CI 0.00–0.41; P < 0.05). Among symptoms,
only headache (OR 0.40; 95% CI 0.25–0.66; P < 0.01) and abdom-
inal/stomach pain (OR 0.56; 95% CI 0.34–0.91; P < 0.05) were
statistically significantly correlated, with a protective effect vs.
the odds of death.
Factors and symptoms associated with hospitalisation
among EVD+ cases
Table 5 shows the factors (section A) and symptoms (section B)
associated with hospitalisation among EVD+ cases.
Among factors, at the multivariable analysis, EVD+ male
patients (OR 1.60; 95% CI 1.10–2.39; P < 0.01), aged 6–15 (OR
2.91; 95% CI 1.06–8.29; P < 0.05) and >30 years (OR 3.55; 95%
CI 1.48–8.72; P < 0.01), were more likely to be hospitalised, as
well as EVD+ cases from Kunike (OR 2.34; 95% CI 1.23–4.57;
P < 0.05) and Yoni chiefdoms (OR 2.06; 95% CI 1.14–3.79;
P < 0.05) and EVD+ cases reporting a contact with an EVD+ or
suspected/probable case (OR 2.45; 95% CI 1.12–5.48; P < 0.05).
Among symptoms, EVD+ cases that presented at the HCF/
ETC/ETU admission with difficult breathing (OR 5.43; 95% CI
1.89–23.0; P < 0.05) and unexplained bleeding (OR 1.64; 95% CI
1.10–2.65; P < 0.05) were more likely to be hospitalised.
Assessment of key-performance indicators for EVD response
Table 6 shows the values of key-performance indicators for EVD
response attained in Tonkolili district compared with the WHO/
MoH targets.
The median interval from symptom onset to alert generation
was 4 days (range: 0–28), with 25.1% of alerts generated within
1 day from symptom onset. Among the 53 alerts related to
HCWs, 11 (20.7%) resulted EVD+. Out of 4550 alerts, 3798
(83.5%) were laboratory investigated (81.8% from alive and
84.4% from dead patients). The median interval from alert gener-
ation to sample collection was 0 days (range: 0–20), with 79.4% of
Table 1. Characteristics of the study population by Ebola virus disease case definition, Tonkolili district, Sierra Leone, 1 July 2014–30 June 2015 (n = 4550)
Characteristics
EVD+ (n = 454) EVD− (n = 3344) EVD suspected and probable (n = 752)a Total (n = 4550)
N (%) N (%) N (%) N (%)
Gender Male 197 (43.4) 1719 (51.4) 386 (51.3) 2302 (50.6)
Female 257 (56.6) 1625 (48.6) 366 (48.7) 2248 (49.4)
Age group <6 year 25 (5.5) 1188 (35.5) 226 (30.1) 1439 (31.6)
6–15 years 52 (11.5) 208 (6.2) 60 (8.0) 320 (7.0)
16–30 years 160 (35.2) 672 (20.1) 117 (15.6) 949 (20.9)
>30 year 217 (47.8) 1276 (38.2) 349 (46.4) 1842 (40.5)
Chiefdom of residence Gbonkolenken 76 (16.7) 625 (18.7) 99 (13.2) 800 (17.6)
Kafe Simiria 5 (1.1) 107 (3.2) 37 (4.9) 149 (3.3)
Kalansogoia 0 (0.0) 125 (3.7) 19 (2.5) 144 (3.2)
Kholifa Mabang 3 (0.7) 108 (3.2) 26 (3.5) 137 (3.0)
Kholifa Rowalla 126 (27.8) 656 (19.6) 142 (18.9) 924 (20.3)
Kunike 77 (17.0) 291 (8.7) 102 (13.6) 470 (10.3)
Kunike Barina 6 (1.3) 175 (5.2) 32 (4.3) 213 (4.7)
Malal Mara 8 (1.8) 127 (3.8) 61 (8.1) 196 (4.3)
Sambaya Bendugu 0 (0.0) 30 (0.99) 5 (0.7) 35 (0.8)
Tane 51 (11.2) 223 (6.7) 51 (6.8) 325 (7.1)
Yoni 93 (20.5) 668 (20.0) 145 (19.3) 906 (19.9)
Outside districts 9 (2.0) 209 (6.3) 33 (4.4) 251 (5.5)
Occupation Health care worker 11 (2.4) 23 (0.7) 19 (2.5) 53 (1.2)
Other occupation 443 (97.6) 3321 (99.3) 733 (97.5) 4497 (98.8)
Hospitalised Yes 303 (66.7) 1316 (39.4) 335 (44.5) 1954 (42.9)
No 151 (33.3) 2028 (60.6) 417 (55.5) 2596 (57.1)
Type of alerts Dead 93 (20.59 2355 (70.4) 451 (60.0) 2899 (63.7)
Alive 361 (79.5) 989 (29.6) 301 (40.0) 1651 (36.3)
EVD+, Ebola laboratory-confirmed cases; EVD−, Ebola laboratory-excluded cases.
aEVD suspected cases = 699; EVD probable cases = 53.
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samples collected within 1 day from the alert; while the median
interval from sample collection to sample testing was 1 day
(range 0–20), with 75.2% of samples tested within 1 day from col-
lection. The median interval from death-to-burial was 0 days
(range: 0–9), with 97.9% buried within 1 day from death.
Furthermore, 62.8% of hospitalisations (n = 1228/1954) occurred
within 3 days from symptom onset, and the CFR among EVD+
hospitalised cases was 17.8%. Among the 454 EVD+ cases, 424
(93.4%) were already recorded in a contacts-tracing list.
Finally, according to WHO/MoH targets, the information on
the number of EVD+ survivors (by gender, age group, chiefdom)
was reported in the Tonkolili VHF surveillance system (Table 4,
Table 2. Incidence, mortality and hospitalisation rates (per 100 000 inhabitants) of Ebola virus disease laboratory-confirmed cases (EVD+) by chiefdom, Tonkolili
district, Sierra Leone, 1 July 2014–30 June 2015
Chiefdom N (%)
Dead N
(%)
Hospitalised N
(%)
Incidence
rate
Mortality
rate
Hospitalisation
rate
Inhabitants
N
Gbonkolenken 76 (16.7) 25 (26.9) 51 (16.8) 127.6 42.0 85.6 59 558
Kafe Simiria 5 (1.1) 2 (2.2) 2 (0.7) 20.1 8.0 8.1 24 901
Kalansogoia 0 (0.0) 0 (0.0) 0 (0.0) 0.0 0.0 0.0 21 873
Kholifa Mabang 3 (0.7) 0 (0.0) 3 (1.0) 17.7 0.0 17.7 16 959
Kholifa Rowalla 126 (27.8%) 29 (31.2) 71 (23.4) 209.0 48.1 117.8 60 289
Kunike 77 (17.0) 5 (5.4) 61 (20.1) 118.3 7.7 116.7 65 105
Kunike Barina 6 (1.3%) 1 (1.1) 2 (0.7) 34.3 5.7 11.4 17 502
Malal Mara 8 (1.8) 3 (3.2) 6 (2.0) 39.8 14.9 29.8 20 117
Sambaia Bendugu 0 (0.0) 0 (0.0) 0 (0.0) 0.0 0.0 0.0 28 503
Tane 51 (11.2%) 8 (8.6) 34 (11.2) 191.3 30.0 127.6 26 654
Yoni 93 (20.5%) 19 (20.4) 66 (21.8) 81.6 16.7 57.9 113 922
other districts
(imported)
9 (2.0) 1 (1.1) 7 (2.3) N.e. N.e. N.e. N.e.
Total 454 (100) 93 (100) 303 (100) 99.7 20.4 66.5 455 383
N.e., not estimable.
Fig. 1. Number of alerts by epi-week, months, year and EVD case definition. Tonkolili, Sierra Leone, 1 July 2014–30 June 2015 (n = 4550). EVD+, Ebola laboratory-
confirmed cases; EVD−, Ebola laboratory-excluded cases; PROB and SUSP, Ebola probable and suspected cases.
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section A), as well as the number of contacts traced per EVD+
case, with an average of 21 individuals (range: 11–79).
Logistic regression model assessing the achievement of indica-
tors over the time and by chiefdom (Table 7) showed gaps in the
last trimester of the study (April–June 2015), when the odds that
an alert was generated within 1 day from symptoms onset was
40% lower (OR 0.61; 95% CI 0.43–0.87; P < 0.05); whilst no differ-
ences were observed over the time for the other indicators, which
were all statistically significant above the OR of 1.00.
Concerning the number of sample tested within 1 day of col-
lection, several chiefdoms had a statistically significant lower odd
of reaching the target. The same was observed with the number of
deaths occurred at the HCF/ETC/ETU and in the community
tested for EBOV, with several chiefdoms showing a statistically
significant lower odd of reaching the indicator. Finally, only the
chiefdom of Kafe Simiria had a statically significant odd that
the hospitalisation occurred within 3 days from symptom onset
(OR 1.99; 95% CI 1.07–3.92; P < 0.05).
Discussion
This study presents first whole epi-data on the EVD outbreak in
Tonkolili district, showing how the VHF database can be used to
identify risk factors and to measure MoH/WHO key-performance
indicators for EVD response.
EVD transmission in Tonkolili district began in August 2014
in the chiefdom of Kholifa Rowalla that showed the highest
EVD+ IR at the end of the outbreak; but before the implementa-
tion of the EVD CEBS/VHF surveillance system in Tonkolili (July
2014), many suspected/probable cases may have never been
reported, investigated and tested for EVD, as suggested in the
Table 3. Risk factors associated with Ebola virus disease. Univariate (row χ2) and multivariable analyses (EVD+ vs. EVD−). Tonkolili District, Sierra Leone, 1 July
2014–30 June 2015 (n = 3798)
Factors
EVD+
(n = 454)
EVD−
(n = 3344)
Total
(n = 3798) Univariate analysis
Multivariable
analysisd
N (%) N (%) N OR (95% CI) OR (95% CI)
Gender Male 197 (10.3) 1719 (89.7) 1916 0.72 (0.59–0.88)a
Female 257 (13.7) 1625 (86.3) 1882 1.38 (1.13–1.68)a Ref
Age group <6 years 25 (2.1) 1188 (97.9) 1213 0.11 (0.07–0.16)a Ref
6–15 years 52 (20.0) 208 (80.0) 260 1.95 (1.41–2.69)a
16–30 years 160 (19.3) 672 (80.7) 832 2.16 (1.75–2.77)a 1.02 (1.00–1.03)b
>30 years 217 (14.5) 1276 (75.5) 1493 1.48 (1.22–1.81)a
Chiefdom of
residence
Gbonkolenken 76 (10.8) 625 (89.2) 701 0.87 (0.67–1.13)c
Kafe Simiria 5 (4.5) 107 (95.5) 112 0.33 (0.13–0.83)b
Kalansogoia 0 (0.0) 125 (100.0) 125 N.e. N.e.
Kholifa Mabang 3 (2.7) 108 (97.3) 111 0.19 (0.06–0.63)a
Kholifa Rowalla 126 (16.1) 656 (83.9) 782 1.57 (1.26–1.96)a Ref
Kunike 77 (20.9) 291 (79.1) 368 2.14 (1.63–2.81)a
Kunike Barina 6 (3.3) 175 (96.7) 181 0.24 (0.10–0.55)a
Malal Mara 8 (5.9) 127 (94.19) 135 0.45 (0.22–0.93)b
Sambaya
Bendugu
0 (0.0) 30 (100.0) 30 N.e. N.e.
Tane 51 (18.6) 223 (81.4) 274 1.77 (1.28–2.44)a
Yoni 93 (12.2) 668 (87.8) 761 1.03 (0.80–1.31)c
Outside districts 9 (4.1) 209 (95.9) 218 0.30 (0.15–0.59)a
Occupation Health care
worker
11 (32.49 23 (67.6) 34 3.58 (1.73–7.40)a 0.90 (0.86–0.94)a
Other occupation 443 (11.8) 3321 (88.2) 3764 0.28 (0.14–0.58)a Ref
Contact with EVD Yes 424 (91.2) 41 (8.8) 465 7.39 (3.51–15.05)a 2.47 (2.44–2.50)a
No 30 (0.1) 3303 (99.1) 3333 0.61 (0.32–0.77)a Ref
Funeral attendance Yes 45 (11.2) 358 (88.8) 403 1.09 (0.78–1.51)c 1.02 (1.01–1.04)a
No 409 (12.0) 2986 (88.0) 3395 0.91 (0.66–1.27)c Ref
EVD+, Ebola laboratory-confirmed cases; EVD−, Ebola laboratory-excluded cases; OR, odds ratio; N.e., not estimable; Ref, reference value.
aP < 0.01.
bP < 0.05.
cP > 0.05.
dStepwise backward elimination at 10% level (only significant variables listed).
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literature [25] and by the fact that the number of alerts increased
exponentially with time.
Overall, during the 1-year study period, 454 EVD+ cases were
reported by the VHF surveillance system of Tonkolili district, with
the last on 15 March 2015. After the study period, other three
EVD+ cases occurred in Tonkolili district: on the 24 July 2015
[14], 13 September 2015 and 14 January 2016 [16] leading to
the final total of 457 EVD+ cases declared by WHO and Sierra
Leone MoH [14, 15].
The monthly EVD+ IR in Tonkolili district and Sierra Leone
showed a similar temporal pattern, reaching the peak in
October 2014, when the Tonkolili IR was higher than the national
IR (400.5 vs. 383.1/100 000) [15]. Overall, the Tonkolili district
EVD+ IR was lower than the national IR (99.7 vs. 122.2/100
000 inhabitants) [10], but differences were observed at chiefdom
level with someone not affected (e.g. Kalansogoia and Sambaia
Bendugu) and others (e.g. Kholifa Rowalla) showing a higher IR
compared with the district and national one. Although the central
geographical location of Tonkolili district, the proportion of
EVD+ imported cases was low (2%) compared with that reported
in other districts (Pujehun 18%; Kono 13%) [26, 27].
Concerning risk factors for EVD+, similarly to other studies
[28, 29], no gender-related difference was found. Although con-
trasting, data from the literature [29, 30] seems to consider at
higher risk for EVD+ patients aged 35–44 years, with slight
increase or reduction thereafter. In this study, patients aged 16–
30 years showed an increased odd (at the limit of statistical signifi-
cance) of being EVD+; and this is in line with the age-specific
incidence of EVD reported during the West Africa outbreak,
and probably due to the fact that this age group could be more
exposed to care sick people and in funeral preparations [30].
Differently from other studies conducted during the West
Africa EVD outbreak [30, 31], HCWs of Tonkolili district had a
lower odd of being EVD+ compared with other professional cat-
egories, as confirmed by their small proportion among EVD+
cases (n = 11/454; 2.4%), one of the lowest recorded in Sierra
Leone [32].This finding may have been driven by the impossibil-
ity of further disaggregate work categories in the statistical
models, and this, together with the unavailability of the informa-
tion on the type of HCWs, is a limit of this analysis. On the other
hand, a study conducted in Sierra Leone [33] showed the absence
of EBOV glycoprotein IgG among HCWs compared with other
professional categories, suggesting a lower exposition or a greater
protection to exposition, as also reported in a study conducted in
Guinea [34].
History of contact with confirmed or suspected/probable EVD
cases increased the odd of being EVD+ in this study, being
reported by 93.4% (n = 424/454) of EVD+ cases, similarly to
what observed in smaller studies from other districts of Sierra
Leone [28, 34]. At the multivariable analysis, attending a funeral
and touching/carrying the body was another factor (at the limit of
statistical significance) increasing the odd of EVD+, as reported in
a meta-analysis on Ebola-transmission risk factors [28] and in a
study from Moyamba district in Sierra Leone [35].
The EVD+ mortality rate in Tonkolili district was lower than
that of Sierra Leone (20.4 vs. 50.4/100 000 inhabitants), with all
the chiefdoms reporting values below the national morality rate
[3]. Also the EVD+ CFR was lower in Tonkolili district compared
with the one at national level (24.5% vs. 41.2%), and with the CFR
of other Sierra Leonean districts (Pujehun 85.7%, Kono 64%,
Moyamba 58%) [26, 27, 36].
Concerning risk factors for death among EVD+ cases, no dif-
ference was found by gender and age group. In a nation-wide
retrospective study conducted in Guinea, the age was the only fac-
tor independently associated with EVD-related mortality [37], as
in another smaller study from Sierra Leone [38]; no gender-
related differences were instead found in both studies, differently
from a study performed at West Africa level, where male sex was
associated with death [39]. The observation that the longer was
the interval from symptom onset to hospitalisation the lower
was the odd of death may be related to symptoms’ severity, pos-
sibly because more severe cases may seek medical care earlier [40].
Abdominal pain and headache were symptoms associated with a
protective effect vs. the odd of death; this could be explained by
the fact that patients reporting these two symptoms had not
more severe clinical presentation, and on the other hand, patients
Table 6. Assessment of Word Health Organization and Sierra Leone Ministry of Health indicators for Ebola response in Tonkolili district, Sierra Leone, 1 July 2014–30
June 2015
Indicator Tonkolili district N (%) WHO/MoH target
Percentage of alert generated within 1 day from symptoms onset 1141 (25.1) 100%
Number and percentage of health care workers infected 11 (20.7) 0%
Percentage of samples tested within 1 day of collection 2857 (75.2) 100%
Percentage of deaths buried within 1 day a 2841 (97.9) 100%
Percentage of lives alert tested for Ebola virus 1350 (81.8) 100%
Percentage of deaths alert tested for Ebola virus 2448 (84.4) 100%
Percentage of reported community deaths that were tested for Ebola virus 1638 (82.2) 100%
Percentage of new confirmed cases from registered contacts 424 (93.4) 100%
Number of hospitalised within 3 days from symptom onset 1228 (62.8) 100%
Case fatality rate among hospitalised EVD+ cases 54 (17.8) <60%
Number of Ebola survivors by gender, age group, chiefdom Reported Reported
Number of contacts traced per EVD+ case Reported Reported
aAll burials (safe and dignified burials and not).
WHO, World Health Organization; MoH, Ministry of Health; EVD+, Ebola laboratory-confirmed cases.
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with severe symptoms might have not been able to report these
two mild symptoms.
Although in the present study, the hospitalisation was not
associated with death, as instead reported in the literature [41],
EVD+ cases from Kunike-chiefdom showed a protection vs. the
odd of death and also had more probability to be hospitalised,
suggesting a protective effect of the hospitalisation. On this
regard, in Tonkolili district, there were only two ETCs: one was
at the Magburaka hospital (Bombalì District), and one was an
Médecins Sans Frontières’ (MSF) ETC opened in December
2014 in Kholifa Rowalla chiefdom [42]. Kunike was not the closer
chiefdom to these ETCs, and Kholifa Rowalla had not the highest
hospitalisation rate, suggesting no effect of the ETC’s proximity
on the chance to be hospitalised and on the risk of death.
Also EVD+ cases with history of contact with EVD+ or sus-
pected/probable cases and with unexplained bleeding were more
likely to be hospitalised, suggesting an effective implementation
of the contact-tracing process. Findings related to EVD+ hospital-
isation cannot be compared with others, due to the lack of these
data in the literature.
Observed key-time periods were similar with those reported in
the literature. The median EVD incubation period was 11 days, in
line with what reported from Pujehun district (10 days) [25] and
from a meta-analysis (10.3 days) [27]. The observed median inter-
vals from symptom onset to death and to hospitalisation were 6
and 3 days, respectively, similarly to what reported from
Pujehun (5.7 and 4.5 days, respectively) [25].
Globally, the assessment of WHO/MoH key-performance
indicators for EVD response found gaps mainly related to the
interval from symptom onset to alert generation in particular in
the last trimester of the study, and this is probably due to the
exponential increase in the number of alerts over the time.
Acceptable performances were observed once the alert is gener-
ated, even if 25% of samples were not collected <1 day from the
alert.
A comparison of these indicators with those attended in other
districts is not possible due to the lack of data in the literature.
Albeit beyond the objectives of the study, it is noteworthy to be
underlined that the CFR among EVD or suspected/probable cases
was extremely high (68.5%, n = 2806/4096), but data on cause of
death were not available. This high mortality is strictly related to
the chronic weakness of health systems of resource-limited coun-
tries in Africa that can easily collapse when epidemics, as the EVD
outbreak, strikes [43].
A limitation of this study is related to the broad age groups
used in order to improve the stability of the multivariable
model, though this has not prevented to identify specific age
group at increased risk for EVD+ in the district. As reported in
the literature [44], another limitation is due to the fact that the
number of true cases of EVD may be ⩾2.5 times that of reported
cases and consequently risk factors may be different or have a dif-
ferent weight in the overall picture of the outbreak into the district.
Despite these limitations and differently from the literature [9],
the data quality and data completeness of the Tonkolili district
VHF database, as indicated, for example, by the fact that all the
454 EVD+ cases had a known risk factor, allowed designing a
clear picture of the EVD outbreak, identifying gaps in the
response and using for the first time EVD– alerts as controls to
identify risk factors; EVD– alerts work as controls of high-quality
because they are generated from the same source of EVD+ alerts.
In conclusion, this study also outlined lessons learned: future
EVD preparedness and response plans for Tonkolili district
should include a chiefdom-vision approach and community-
based strategy of social-mobilisation activities targeting Ebola
knowledge-attitudes-practice (a) during funeral attendance (b)
to avoid contact with EVD+ or suspected/probable cases and
(c) to increase awareness on EVD symptoms, in order to reduce
the delays between symptom onset and treatment seeking and
so the delays between symptom onset and alert generation that
consequently affect the promptness of the outbreak response.
Supplementary material. The supplementary material for this article can
be found at https://doi.org/10.1017/S0950268819000177.
Author ORCIDs. Alessandro Miglietta, 0000-0002-5841-6645
Acknowledgements. Authors are pleased to acknowledge the dedicated
efforts of staff involved in the Ebola outbreak response and all numerous
national and international organisations responding to the Ebola epidemic.
In particular, we are grateful to the staff working for the Tonkolili DERC
and DHMT.
Financial support. This research received no specific grant from any fund-
ing agency, commercial or not-for-profit sectors.
Conflict of interest. None.
Author contributions. Alessandro Miglietta conceptualised the research and
was the EVD surveillance pillar of Tonkolili district during the outbreak.
Together with Gianluca Russo wrote the initial draft. Angelo Solimini and
Alessandro Miglietta designed the methodology and performed the statically
analyses. Ghyslaine Bruna Djeunang Dongho and Carla Montesano reviewed
the initial manuscript. Giovanni Rezza, Vincenzo Vullo, Vittorio Colizzi and
Gianluca Russo supervised the research and critically reviewed the final sub-
mitted manuscript.
References
1. Feldmann H and Geisbert TW (2011) Ebola haemorrhagic fever. Lancet
377, 849–862.
2. Marí Saéz A et al. (2014) Investigating the zoonotic origin of the West
African Ebola epidemic. EMBO Molecular Medicine 7, 17–23.
3. World Health Organization (2017) Ebola Virus Disease, fact sheet. Available
at www.who.int/mediacentre/factsheets/fs103/en (Accessed 14 June 2017).
4. Sissoko D et al. (2017) Persistence and clearance of Ebola virus RNA from
seminal fluid of Ebola virus disease survivors: a longitudinal analysis and
modelling study. Lancet Global Health 5 , 80–88.
5. Johnson KM et al. (1977) Isolation and partial characterisation of a new
virus causing acute haemorrhagic fever in Zaire. Lancet 1, 569–571.
6. Baize S et al. (2014) Emergence of Zaire Ebola virus disease in Guinea.
New England Journal of Medicine 371, 1418–1425.
7. World Health Organization (2016) Last Ebola Situation Report. Available
at http://apps.who.int/ebola/current-situation/ebola-situation-report-30-
march-2016 (Accessed 13 April 2017).
8. World Health Organization (2014) Statement on the 1st meeting of the
IHR Emergency Committee on the 2014 Ebola outbreak in West Africa.
Available at www.who.int/mediacentre/news/statements/2014/ebola-
20140808/en/ (Accessed 7 January 2017).
9. Li QF et al. (2016) Transmission dynamics of Ebola virus disease and
intervention effectiveness in Sierra Leone. Proceedings of the National
Academy of Sciences of the USA 113, 4488–4493.
10. Ministry of Health and Sanitation, Republic of Sierra Leone (2015)
Ebola Situation Report_Vol 504. Available at http://health.gov.sl/?
page_id=583 (Accessed 7 January 2017).
11. World Health Organization (2016) Statement on the 9th meeting of the
IHR Emergency Committee regarding the Ebola outbreak in West Africa.
Available at http://www.who.int/mediacentre/news/statements/2016/end-
of-ebola-pheic/en/ (Accessed 4 April 2017).
12. Centers for Disease Control and Prevention (2016) Cost of the Ebola
Epidemic. Available at https://www.cdc.gov/vhf/ebola/history/2014-2016-
outbreak/cost-of-ebola.html#N3 (Accessed 13 November 2018).
Epidemiology and Infection 13
:DD$C,*** 53!4%697 #%95#%7D7%!C :DD$C,6# #%9 2

.#*" #36768%#!:DD$C,*** 53!4%697 #%95#%7 01366%7CC,
  
 #"/743D,,	C(475DD#D:73!4%697#%7D7%!C#8(C73F3 34 73D
13. United Nations Office for the Coordination of Humanitarian Affairs
(OCHA) (2015) Sierra Leone- Tonkolili-District profile. Available at
http://reliefweb.int/sites/reliefweb.int/files/resources/final_District_profile_
template_western_rural_10_dec_2015am%20%281%29_0.pdf (Accessed
7 January 2017).
14. World Health Organization. Ebola data and statistics (2016) Graphs of
new confirmed cases by epi week and District. Available at http://apps.
who.int/gho/data/view.ebola-sitrep.ebola-country-SLE-new-conf-prob-districs-
20160511-graphs?lang=en (Accessed 7 January 2017).
15. Ministry of Health and Sanitation, Republic of Sierra Leone (2016)
Ebola Situation Report–Vol 473. Available at http://health.gov.sl/?
page_id=583 (Accessed 7 January 2017).
16. World Health Organization (2016) WHO Statement: new Ebola case in
Sierra Leone. WHO continues to stress risk of more flare-ups. Available
at http://www.who.int/mediacentre/news/statements/2016/new-ebola-case/
en/ (Accessed 7 January 2017).
17. World Health Organization (2015) Sierra Leone: tracing Ebola in
Tonkolili. Available at www.who.int/features/2015/tracing-abola-tonko-
lili/en/ (Accessed 7 January 2017).
18. Centers for Disease Control and Prevention (2014) CDC Disease
Detectives Using New Software Tool in Ebola Hemorrhagic Fever
Outbreak. Available at www.cdc.gov/media/releases/2014/p0492-new-soft-
ware.html (Accessed 13 February 2017).
19. World Health Organization (2016) Key indicators relevant to Ebola out-
break. Available at http://apps.who.int/gho/data/node.ebola (Accessed 7
January 2017).
20. World Health Organization & US Centers for Disease Control and
Prevention (2015) Implementation and management of contact tracing
for Ebola virus disease. Emergency Guideline. Available at http://apps.
who.int/iris/bitstream/10665/185258/1/
WHO_EVD_Guidance_Contact_15.1_eng.pdf (Accessed 7 January 2017).
21. McNamara LA et al. (2016) Ebola Surveillance – Guinea, Liberia, and
Sierra Leone. Morbidity and Mortality Weekly Report 65 , 35–43.
22. World Health Organization (2014) Case definition recommendations for
Ebola or Marburg virus diseases. Available at http://www.who.int/csr/
resources/publications/ebola/ebola-case-definition-contact-en.pdf
(Accessed 7 January 2017).
23. Towner JS et al. (2004) Rapid diagnosis of Ebola hemorrhagic fever by
reverse transcription-PCR in an outbreak setting and assessment of patient
viral load as a predictor of outcome. Journal of Virology 78, 4330–4441.
24. Hosmer Jr. DW and Lemeshow S (2004) Applied Logistic Regression. New
York: John Wiley & Sons.
25. World Health Organization (2016) Ebola in Sierra Leone: A slow start to
an outbreak that eventually outpaced all others. Available at http://www.
who.int/csr/disease/ebola/one-year-report/sierra-leone/en/ (Accessed 7 January
2017).
26. Ajelli M et al. (2015) The 2014 Ebola virus disease outbreak in Pujehun,
Sierra Leone: epidemiology and impact of interventions. BMC Medicine
26, 213–281.
27. Stehling-Ariza et al. (2016) The impact of active surveillance and health
education on an Ebola virus disease cluster – Kono District, Sierra Leone,
2014–2015. BMC Infectious Diseases 27, 16–611.
28. Brainard J et al. (2016) Risk factors for transmission of Ebola or Marburg
virus disease: a systematic review and meta-analysis. International Journal
of Epidemiology 45 , 102–116.
29. Bower H et al. (2016) Exposure-specific and age-specific attack rates for
Ebola virus disease in Ebola-affected households, Sierra Leone. Emerging
Infectious Disease 22, 1403–1411.
30. Glynn JR (2015) Age-specific incidence of Ebola virus disease. Lancet 386,
9992–99432.
31. Kilmarx PH et al. (2014) Ebola virus disease in health care workers-Sierra
Leone, 2014. Morbidity and Mortality Weekly Report 63, 1168–1171.
32. World Health Organization (2015) Health worker Ebola infections in
Guinea, Liberia and Sierra Leone. A preliminary report. Available at
http://apps.who.int/iris/bitstream/10665/171823/1/WHO_EVD_SDS_REPORT_
2015.1_eng.pdf?ua=1&ua=1 (Accessed 10 July 2017).
33. Glynn JR et al. (2017) Asymptomatic infection and unrecognised Ebola
virus disease in Ebola-affected households in Sierra Leone: a cross-
sectional study using a new non-invasive assay for antibodies to Ebola
virus. Lancet Infectious Disease 17, 645–653.
34. Hélène S et al. (2017) Occupational exposures to Ebola virus in Ebola treat-
ment center, Conakry, Guinea. Emerging Infectious Disease 23, 1380–1383.
35. Haaskjold Y et al. (2016) Clinical features of and risk factors for fatal
Ebola virus disease, Moyamba district, Sierra Leone, December 2014–
February 2015. Emerging Infectious Disease 22, 1537–1544.
36. Curran KG et al. (2016) Cluster of Ebola virus disease linked to a single
funeral – Moyamba district, Sierra Leone, 2014. Morbidity and Mortality
Weekly Report 65 , 202–205.
37. Cherif MS et al. (2017) The predictor of mortality outcome in adult patients
with Ebola virus disease during the 2014–2015 outbreak in Guinea.
European Journal of Clinical Microbiology & Infectious Disease 36, 689–695.
38. Qin E et al. (2015) Clinical features of patients with Ebola virus disease in
Sierra Leone. Clinical Infectious Diseases 61, 491–495.
39. Agua-Agum J et al. (2016) Ebola virus disease among male and female
persons in West Africa. The New England Journal of Medicine 374, 96–98.
40. Wong JY et al. (2016) Assessment of the severity of Ebola virus disease in
Sierra Leone in 2014–2015. Epidemiology & Infection 144, 1473–1481.
41. Harsha Moole et al. (2015) Association of clinical signs and symptoms of
Ebola viral disease with case fatality: a systematic review and meta-analysis.
Journal of Community Hospital Internal Medicine Perspectives 5, 4–10.
42. Theocharopoulos G et al. (2017) Ebola management centre proximity
associated with reduced delays of healthcare of Ebola virus disease
(EVD) patients, Tonkolili, Sierra Leone, 2014–15. PLoS ONE 1, 12–25.
43. O’Hare B (2015) Weak health systems and Ebola. Lancet Global Health 3,
71–82.
44. Meltzer M et al. (2014) Estimating the future number of cases in the
Ebola epidemic – Liberia and Sierra Leone, 2014–2015. Morbidity and
Mortality Weekly Report 63, 1–14.
14 Alessandro Miglietta et al.
:DD$C,*** 53!4%697 #%95#%7D7%!C :DD$C,6# #%9 2

.#*" #36768%#!:DD$C,*** 53!4%697 #%95#%7 01366%7CC,
  
 #"/743D,,	C(475DD#D:73!4%697#%7D7%!C#8(C73F3 34 73D
